Meta-Analysis
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Aug 24, 2025; 16(8): 106873
Published online Aug 24, 2025. doi: 10.5306/wjco.v16.i8.106873
Adding programmed death 1/programmed death ligand 1 inhibitors to first-line standard-of-care therapy for metastatic colorectal cancer: A meta-analysis
Ting Zheng, Xing-Xing Li, Li Zhou, Jian-Jiang Jin
Ting Zheng, Xing-Xing Li, Li Zhou, Jian-Jiang Jin, Department of Medical Oncology, The First People’s Hospital of Linping District, Hangzhou 311100, Zhejiang Province, China
Author contributions: Zheng T and Li XX conceived and designed the study and performed statistical analyses; Zhou L and Jin JJ collected data and performed the database search; Zheng T, Li XX, Zhou L, and Jin JJ drafted the manuscript; Zheng T and Zhou L confirmed the authenticity of the raw data; All authors revised the manuscript and read and approved the final manuscript.
Conflict-of-interest statement: All authors report no relevant conflicts of interest for this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ting Zheng, Department of Medical Oncology, The First People’s Hospital of Linping District, No. 369 Yingbin Road, Linping District, Hangzhou 311100, Zhejiang Province, China. zz_tt666@163.com
Received: March 10, 2025
Revised: April 23, 2025
Accepted: June 24, 2025
Published online: August 24, 2025
Processing time: 163 Days and 17.4 Hours
Core Tip

Core Tip: We performed a meta-analysis to evaluate the efficacy and safety of combining inhibitors of programmed death 1 or its ligand with standard-of-care therapy as first-line treatment for metastatic colorectal cancer. Results showed integrating inhibitors of programmed death 1 or its ligand failed to demonstrate significant improvements in the overall response rate. Existing clinical data remain inadequate to establish overall survival advantages, particularly in patients with microsatellite stable/mismatch repair-proficient, despite exhibiting manageable toxicity profiles.